anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Anorexia, malaise, abdominal discomfort or pain, dysphagia, nausea, vomiting, and diarrhea have occurred. These are more frequent with large doses or after one to three months of continuous therapy.

A few patients have had sudden onset of profuse, watery diarrhea. Discontinue Ethacrynic acid if diarrhea is severe and do not give it again. Gastrointestinal bleeding has occurred in some patients. Rarely, acute pancreatitis has been reported.
There is an opioid epidemic in the United States, and the epidemic continues to worsen. The rate of opioids prescribed, distributed, and deaths from opioid overdoses continue to increase steadily. Opioids also have the costs of abuse, dependence, diversion of unused medication, and can serve as a gateway to other illegal substances. Opioid use often begins with treatment of acute postoperative pain, and the surgical episode can be a 'gateway' to the opioid crisis. Opioids remain ubiquitous in patients undergoing surgical procedures. Among opioid-naïve patients, persistent use after surgery occurs in 6-10%.

Ambulatory surgery cases are rarely mentioned in the context of this public health crisis, but are a major contributor to the problem. Opioids are ubiquitous after ambulatory anorectal surgery and prescribed in large quantities, often several times more than what is needed or taken by patients. As patients take a fraction of the opioids prescribed, this adds to issues of opioid diversion. In colorectal surgery, ambulatory anorectal procedures are common and frequent procedures, with the potential to impact a large number of patients when implementing quality improvement. Thus, study into ERAS and ways to reduce opioids after ambulatory anorectal surgery is warranted.

This application challenges the notion that inpatient surgery should be the only target for enhanced recovery and opioid interventions. It seeks to shift the clinical practice paradigm that extended opioids are necessary after ambulatory anorectal surgery. This new application of ERAS to ambulatory anorectal surgery could address a critical barrier to progress in reducing opioids in procedures that are common but underrepresented in current research.
PROBLEM TO BE SOLVED: To provide a colorant that is capable of reversibly changing color and contains a natural coloring which is in safe for the human body and to produce a cosmetic material containing a natural coloring matter capable of changing color in a red color tone by using the colorant. SOLUTION: The colorant comprises a powder prepared by drying a fruit of Capsicum Annuum belonging to plants in the family Solanaceae. An antimicrobial agent may be further added to the colorant. A cosmetic material containing the colorant can be produced. The colorant exhibits an orange color in its dry state and exhibits a red color tone from a red color to a deep red color preferably on condition that the colorant is brought into contact with moisture or an oily component in a weak acid zone to absorb it. The color change reaction reversibly takes place.
Detection of microbial DNA is a primary means of host defense. In mammalian cells, DNA-sensing pathways induce robust anti-microbial responses and initiation of adaptive immunity, leading to the eventual clearance of the infectious agent. However, while conferring the advantage of broad detection capability, the sequence-independent recognition mechanisms of most DNA sensors pose a significant challenge for mammalian cells to maintain ignorance to self-DNA under homeostatic conditions. In this Review, we summarize the fundamentals of DNA-sensing pathways and the intricate regulatory networks that keep these pathways in check. In addition, we describe how regulatory restraints can be defective and underlie human autoinflammatory and autoimmune diseases. Further, we discuss therapies in development that limit inflammation fueled by self-DNA or inappropriate activation of DNA-sensing pathways.
The Netherlands' cervical cancer screening program transitioned to primary human papillomavirus (HPV) screening in 2017. After the introduction of HPV-based screening, the country saw increases in colposcopy referral rates and detections of low-grade lesions. In July 2022, genotyping was introduced, and those with borderline or mild dyskaryotic (BMD) cytologic abnormalities were only referred to colposcopy if positive for HPV type 16 or 18, and repeat screening otherwise. In this article, various strategies using extended genotyping (HPV16/18/31/33/45/52/58) as a triage test after an abnormal screen were explored using data from HPV-positive participants with normal or BMD cytology in the Population-Based Screening Study Amsterdam (POBASCAM) trial. The authors assessed positive and negative predictive values and colposcopy referral rates for each strategy using extended genotyping to triage women to either direct referral to colposcopy or repeat screening. Direct referral did not meet positive and negative predictive value thresholds for efficiency for any strategies. However, the authors note that direct referral may nonetheless be useful among those with BMD due to minimal increases in colposcopy referrals and concerns of loss to follow-up at repeat screening. These findings demonstrate the potential utility of extended genotyping as a triage test in primary HPV screening programs. The results should be considered alongside the fact that referral to repeat screening may result in loss of engagement of women who need treatment to prevent invasive cancer. See related article by Kroon et al., p. 1037.
For the past 6 decades, uncuffed tubes have been used for the children less than 8 years of age out of a fear that cuffed tubes would cause damage to the subglottic region. The correct size uncuffed tube creates a seal in the subglottis that has minimal pressure on the mucosa. However, cuffed tubes have become more widely used in children recently without causing damage to the mucosa. There is very little literature comparing the magnitude of the gas leaks with cuffed and uncuffed tracheal tubes particularly in children. Several authors suggest that the leak of nitrous oxide and sevoflurane with uncuffed tubes was much greater than with cuffed tubes. One important but poorly studied issue is the risk of an airway fire when cautery is used for tonsillectomy because a large leak of oxygen in the mouth could ignite a fire. It also remains unclear whether the mode of ventilation, spontaneous or controlled, affects the leak of gases into the mouth. One might expect that the gas leak with spontaneous ventilation is less than with controlled ventilation, but it may not matter in the context of the small concentrations of oxygen and sevoflurane that investigators use. To address all of these concerns, investigators designed this study to compare the concentrations of gases (oxygen, carbon dioxide, nitrous oxide and sevoflurane) in the oral cavity of children undergoing T\&A with either cuffed or uncuffed tubes, during spontaneous and controlled ventilation.
JNT-517 or placebo daily for 4 weeks. Dose is based on data from Parts A, B, and C.
The utility model discloses a novel facial mask display board, and relates to the technical field of facial auxiliary articles. The novel facial mask display board comprises a first transparent resin face plate, a second transparent resin face plate, set screws, a first supporting screw and a second supporting screw. The second transparent resin face plate is arranged on the first transparent resin face plate. The first transparent resin face plate and the second transparent resin face plate overlap and are fixed through the set screws to form a regular isosceles triangle. The first supporting screw and the second supporting screw are arranged on the left side of the lower end bottom edge of the first transparent resin face plate and the right side of the lower end bottom edge of the first transparent resin face plate respectively. The novel facial mask display board is reasonable in structural design, attractive in appearance and novel and unique in modeling; by means of 68-degree arc and elliptic segmentation and partition, the display state of a piece of facial mask paper completely conforms to the golden section rule, the form of the facial mask paper is displayed in an all-dimensional and three-dimensional mode, the traditional narrow display concept that a facial mask can only be sensed in a two-dimensional mode is subverted, and consumers can visually know the use state of the facial mask.
Purpose: While there are known disparities in socioeconomic status (SES) and health outcomes among racially and ethnically minoritized adolescent and young adult (AYA; ages 15-39 years at diagnosis) cancer survivors compared with White survivors, outcomes in the Asian survivor population are understudied. To better understand the association of an AYA cancer diagnosis with SES and health outcomes within a minoritized population, the current study makes comparisons between individuals of the same race or ethnicity with and without a history of AYA cancer. Methods: Non-Hispanic, Asian AYA cancer survivors and non-Hispanic, Asian age- and sex-matched controls were identified from self-reported data in the National Health Interview Survey (2009-2020). Prevalence of chronic health conditions and socioeconomic factors were compared between groups using chi-square tests. Odds of chronic conditions by SES factors were determined within and between survivors and controls using logistic regression methods. Results: One hundred and thirty-one survivors and 1310 controls were included. Survivors were less likely to be married compared with controls; however, there were no differences in other SES factors examined. Survivors had higher odds of at least one chronic condition diagnosis (odds ratio = 4.17, p < 0.001) compared with controls. Of the chronic conditions assessed, survivors had higher odds of arthritis, pulmonary disease, and hypertension compared with controls. Conclusions: Asian AYA cancer survivors are at increased risk of chronic health conditions compared with Asian individuals without a cancer history. Culturally adapted targeted interventions are needed to improve health outcomes for this population.
Participants received Placebo for guselkumab at Weeks 0, 4, and 12, and placebo for adalimumab (two 0.8 mL injections) at Week 0, followed by one 0.8 mL injection at Weeks 1, 3, and 5, and q2w through Week 15. At Week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20 and q8w thereafter through Week 252, as well as placebo for adalimumab at Weeks 17, 19, 21, and 23, and q2w thereafter through Week 47.
BACKGROUND: Concerns about the adverse effects of excessive oxygen have grown over the years. This study investigated the relationship between high oxygen saturation and short-term prognosis of patients with spontaneous intracerebral hemorrhage (sICH) after liberal use of oxygen.
METHODS: This retrospective cohort study collected data from the Medical Information Mart for Intensive Care III (MIMIC-III) database (ICU cohort) and a tertiary stroke center (general ward cohort). The data on pulse oximetry-derived oxygen saturation (SpO2) during the first 24 h in ICU and general wards were respectively extracted.
RESULTS: Overall, 1117 and 372 patients were included in the ICU and general ward cohort, respectively. Among the patients from the ICU cohort, a spoon-shaped association was observed between minimum SpO2 and the risk of in-hospital mortality (non-linear P<0.0001). In comparison with minimum SpO2 of 93-97%, the minimum SpO2>97% was associated with a significantly higher risk of in-hospital mortality after adjustment for confounders. Sensitivity analysis conducted using propensity score matching did not change this significance. The same spoon-shaped association between minimum SpO2 and the risk of in-hospital mortality was also detected for the general ward cohort. In comparison with the group with 95-97% SpO2, the group with SpO2>97% showed a stronger association with, but non-significant risk for, in-hospital mortality after adjustment for confounders. The time-weighted average SpO2>97% was associated significantly with in-hospital mortality in both cohorts.
CONCLUSION: Higher SpO2 (especially a minimum SpO2>97%) was unrewarding after liberal use of oxygen among patients with sICH and might even be potentially detrimental.
This is an experimental task shifting of ART initiation and monitoring from a clinician-led model to a nurse-led model. Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
<P>PROBLEM TO BE SOLVED: To provide an artificial tooth stabilizing agent, and an artificial tooth mounting method, by which a comfortable and favorable artificial tooth mounting state can be kept for a long period without causing pain, ulcers, or inflammation, in such a way as to be especially suitable to a toothless jaw patient.  <P>SOLUTION: The artificial tooth stabilizing agent comprises flexible adhesive having a polyvinyl acetate resin with low fluidity in an amount of 3-9 wt.%, dissolved in room temperature valcanizable (RTV) liquid silicone rubber, of de-acetic acid type. In the artificial tooth mounting method, an artificial tooth, to which the stabilizing agent is applied at a mucous membrane contacting part of an artificial tooth bed, is disposed on the mucous membrane after the mouth is rinsed with a saturated solution of pre-conditioned pharmacopeial sodium hydrogencarbonate to penetrate the mucous membrane. While acetic acid emitted from the artificial tooth stabilizing agent is neutralized, an alveolar ridge is modeled, and then it is taken out of the mouth. After the artificial stabilizing agent is vulcanized, the artificial tooth is mounted on the mucous membrane through the false tooth stabilizing agent.  <P>COPYRIGHT: (C)2007,JPO&INPIT
There are 100 patients in the intervention group without automated or observer initiated motivation messages. They receive an individualized training program without regular notifications about their training status via their SmartWatch.
FLT3 is mainly expressed in immune and various cancer cells and is a drug target for acute myeloid leukemia (AML). Recently, FLT3 has also been identified as a potential target for treating chronic pain. Most FLT3 inhibitors (FLT3i) identified to date, including approved drugs such as gilteritinib, midostaurin, ponatinib, quizartinib, and FLT3i in clinical trials, such as quizartinib and crenolanib, also inhibit closely-related kinases that are important for immune (c-KIT), cardiovascular (KDR/VEGFR2, FGFR, PDGFR) or kidney (RET) functions. While the aforementioned FLT3i may increase survival rates in AML, they are neither ideal for AML maintenance therapy nor for non-oncology applications, such as for the treatment of chronic pain, due to their promiscuous inhibition of many kinase anti-targets. Here, we report the identification of new FLT3i compounds that have low activities against kinases that have traditionally been difficult to differentiate from FLT3 inhibition, such as KDR/VEGFR, FGFR, PGFR, c-KIT, and RET. These selective compounds could be valuable chemical probes for studying FLT3 biology in the context of chronic pain and/or may represent good starting points to develop well-tolerated FLT3 therapeutics for non-oncology indications or for maintenance therapy for AML.
During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Gemcitabine monotherapy among 6 patients in the Phase I study.
PURPOSE: A method of making a pharmaceutical preparation containing phenylethanoid glycosides extracted from Cistanche tubulosa(schenk.) wight is provided. The pharmaceutical preparation has excellent efficacy on enhancing memory, preventing senile dementia and inhibiting platelet aggregation. CONSTITUTION: The pharmaceutical preparation contains phenylethanoid glycosides extracted from Cistanche tubulosa(schenk.) wight. The phenylethanoid glycosides comprise 10 to 70% by weight of echinacoside, 1 to 40% by weight of acteoside and additionally 5% or less by weight of 2'-acetylacteoside, campneoside I, campneoside II, crenatoside, isoacteoside, syringalide A, 3'-α-L-rhamnopyranoside and tubuloside A. The phenylethanoid glycosides are obtained by: extracting Cistanche tubulosa(schenk.) wight in water or a mixture of water and ethanol; introducing the extract into a column filled with hydrophilic polymer beads; subjecting the column to an elution process with water; and then subjecting the column to an elution process with a mixture of water and ethanol.
The invention discloses a compound of the traditional Chinese medicine for treating lung cancer and the preparation method. The invention is mainly prepared by zedoary turmeric, semen lepidii astragalus, radix adenophorae, cortex mori, balloon flower, bitter orange, pinellia tuber, perilla leaf, dry skin of toad, ephedra, ginger and liquorice. The compound of the traditional medicine of the invention has the curative effect of purging the lung and removing phlegm, promoting qi circulation for diuresis and removing lump and resolving hard mass. The invention is mainly for treating lung cancer, mass in the lung, retention of damp and phlegm-heat, deficiency of pulmonary and renal qi and so on. The symptoms includes lung invasion of the drunk fluid, cough and phlegm dyspnea, gradual emaciation, failure to utter a word and lie flat, yellow and greasy fur on the tongue and slippery and rapid pulse. The invention with simple formula, easy production, convenient administration and notable curative effect has wide application value.
The present invention provides a composition containing tangeretin as an active ingredient for external application to the skin. The present invention also provides a composition containing tangeretin and EGCG for external application to the skin. The present invention also provides a composition for external application to the skin, comprising, as an active ingredient, mandarin peel extracts containing tangeretin. The present invention also provides a composition for external application to the skin comprising mandarin peel extracts containing tangeretin and further comprising green tea extracts containing Epigallocatechin gallate (EGCG). The composition of the present invention has excellent antioxidative effects and therefore can be applied as a cosmetic composition, a pharmaceutical composition or a health food composition. Further, the composition of the present invention may have superior effects of preventing skin erythema, improving skin tone and preventing skin aging.
Patients will be asked to reduce their smoking during the first 4 days of treatment with aim to quit on the 5th day (target quit date). Cytisine treatment will follow standard manufacturer's dosing protocol of one tablet every 2 hours through the waking day (up to 6 tablets per day) for days 1-3, one tablet every 2.5 hours (up to 5 tablets per day) for days 4-12, one tablet every 3 hours (up to 4 tablets per day) for days 13-16, one tablet every 4-5 hours (3 tablets per day) for days 17-20, and one tablet every 6 hours (2 tablets per day) for days 21-25.
This invention discloses that certain types of zinc compounds, if added to formulations (such as condom lubricants and lubricant gels) that are applied topically to one or more genital surfaces during sexual intercourse, can reduce the irritation caused by spermicidal and/or microbicidal agents, which act essentially as toxins designed to kill various types of cells and microbes. Preferred zinc compounds include zinc lactate, zinc gluconate, zinc acetate, and other water-soluble organic zinc salts. In addition to reducing irritation caused by surfactants (such as nonoxynol or octoxynol) and other microbicides in topical genital formulations, zinc-containing additives can help stabilize and protect cellular membranes, thereby helping protect genital surfaces against damage caused by repeated exposure to agents that attack the lipid membranes that surround mammalian cells. Zinc-containing additives can also help accelerate the healing and closure of lesions or other skin breaches caused by spermicidal or microbicidal toxins, or by abrasion, rashes, sexually transmitted diseases, or other causes. Because of these effects, topical genital formulations containing spermicides or microbicides, and also containg a suitable zinc compound, can promote better skin tone and better genital health and hygiene, compared to similar formulations containing a spermicide and/or microbicide without zinc. In addition, zinc-containing additives can also reduce the risk and severity of allergic reactions to latex proteins in condoms.
This project reflects a basic experimental study involving human participants (BESH), which focuses on the neuroscience of episodic memory. Episodic memory involves the encoding and retrieval of past experiences to support learned behavior. Aside from these mnemonic processes, it also requires the ability to regulate memory (i.e. executive processes). For example, many real-world decisions will engage episodic retrieval, for which executive processes must help to integrate and evaluate the quality of remembered information (mnemonic evidence) and guide behavior to either decision, action, or continued memory search. While the neural basis of episodic memory encoding and retrieval have been a major focus of research, far less is known about its executive aspects. Executive mnemonic functions likely involve an anatomical substrate that is (i) multisensory/associative, (ii) engaged by memory/executive processing, and (iii) strongly interconnected with both mnemonic regions in the medial temporal lobe (MTL) and executive prefrontal (PFC) regions. Prior non-human primate studies, as well as human electrophysiology and neuroimaging data, suggest that posterior cingulate cortex (PCC) fulfills these criteria. The central hypothesis of this work is that the PCC plays a critical and unique role in executive control of episodic memory retrieval. The investigators further hypothesize that it comprises three subregions regions: dorsal PCC, ventral PCC and retrosplenial cortex (RSC). These subregions are proposed to play complementary roles, corresponding to retrieval regulation, retrieval integration, and scene perception and transformation, respectively. In this account, PCC is a convergence zone of memory and executive systems, whose specific functional organization accounts for prior discrepancies between studies and species. The investigators will utilize human intracranial recordings, including single-cell data and stimulation within PCC, to better resolve the functional organization of this region. The investigators will employ an array of cognitive experiments to delineate three PCC subregions supporting the encoding, retrieval and executive control of memory processing (Aim 1). In delineating these subregions, the investigators will also seek to differentiate PCC responses from those occurring in memory and executive functional networks (Aim 2). Finally, based on these observations, the investigators will demonstrate the causal role of PCC subregions on behavior and local/network activity (Aim 3). By studying PCC, a convergence zone of memory and executive systems, progress can be made in elucidating how the failure to successfully leverage past experiences in daily behavior can occur as a common symptom of both neurodegenerative disease (e.g. Alzheimer's disease) and multiple psychiatric conditions (e.g. schizophrenia) implicating PCC dysfunction.